Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
09:09am, Tuesday, 15'th Apr 2025
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields appro
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?
07:39am, Tuesday, 15'th Apr 2025
Pfizer (PFE 0.82%) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candida
Trump Says Pharmaceutical Tariffs Coming in Near Future
02:03pm, Monday, 14'th Apr 2025
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with repo
Trump says US pharma tariffs coming in not-too-distant future
12:26pm, Monday, 14'th Apr 2025
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
11:12am, Monday, 14'th Apr 2025
Bad news for Pfizer (PFE 1.07%) turned into good news for Eli Lilly (LLY 2.42%), Novo Nordisk (NVO 2.23%), and Viking Therapeutics (VKTX 8.48%) Monday morning, each of which is rising on Pfizer's late
Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug
10:45am, Monday, 14'th Apr 2025
Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 10.1% to trade at $24.42 today, and traded as high as $27.09 earlier in the session.
Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'
10:31am, Monday, 14'th Apr 2025
Pfizer (PFE) said it will stop development of an oral daily weight-loss pill after a participant taking the drug in a clinical trial experienced a liver injury.
Pfizer discontinues development of weight loss pill
09:38am, Monday, 14'th Apr 2025
Pfizer Inc (NYSE:PFE, ETR:PFE) announced it will discontinue the development of its experimental weight-loss pill, danuglipron, due to safety concerns. The company said on Monday that the decision com
Pfizer ends development of weight-loss pill danuglipron
06:49am, Monday, 14'th Apr 2025
Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved after the medica
Pfizer scraps daily weight loss pill after liver injury in one patient
06:45am, Monday, 14'th Apr 2025
Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient's liver enz
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
06:45am, Monday, 14'th Apr 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which
Pfizer Halts Development of New Weight-Loss Drug
06:45am, Monday, 14'th Apr 2025
The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.
Danuglipron was the latest drug investors were hinging hope on to enter the obesity market.
As the market dips, I'm eyeing dividend plays like KO and PM – what stocks are on your buy list right now?
12:29pm, Sunday, 13'th Apr 2025
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today.
3 Dividend Stocks for April 2025
11:00am, Sunday, 13'th Apr 2025
This month's trio includes two dividend aristocrats.
